Expert Exchange 2020: Examining The Use Of Newer and Emerging Agents In Bladder Cancer. What Clinicians Need to Know

December 3, 2020

Presented by Creative Educational Concepts, Inc. and Supported by an independent educational grant from AstraZeneca.
 

Target Audience

This activity is designed to meet the educational needs of urologists and urologic oncologists attending the 2020 Virtual Meeting of the Society of Urologic Oncology.

Learning Objectives

At the conclusion of this application-based activity, participants will be able to:

  • Examine the role of immune checkpoint inhibitors across the bladder cancer disease continuum, including in the NMIBC, neoadjuvant, and advanced disease settings.
  • Appraise practical next steps for sequencing of treatments in disease progression.
  • Explore the role of sequential therapy and multimodal and/or combination regimens involving checkpoint inhibitors, FGFR inhibitors, and novel ADC agents.
  • Develop strategies to proactively plan for adverse events that may occur when using checkpoint inhibitors in patients with bladder cancer.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
10/27/2020
Course expires: 
12/03/2020
Event starts: 
12/03/2020 - 11:00am
Event ends: 
12/03/2020 - 12:00pm
Rating: 
0

Neal Shore, MD, FACS (Activity Chair)
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina

 

 

Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, New York

 

Robert Dreicer, MD, MS, MACP, FASCO
Associate Director for Clinical Research 
Deputy Director, University of Virginia Cancer Center 
Co-Director, Paul Mellon Urologic Cancer Institute 
Professor of Medicine and Urology
University of Virginia School of Medicine 
Charlottesville, Virginia

Ashish M. Kamat, MD, MBBS, FACS
Professor, Department of Urology
Division of Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

 


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Susan H. Gitzinger, PharmD, MPH–has disclosed she has no financial disclosures in relation to this activity. 
Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.

Speakers
Arjun V. Balar,MD–has disclosed that he is a consultant for AstraZeneca/Medimmune, Genentech, Immunomedics, Incyte, Janssen, Merck, Nektar, Pfizer, and Seattle Genetics. He receives grant/research support from AstraZeneca/Medimmune (institution), Genentech (institution), Immunomedics (institution), Merck (institution), Nektar, and Seattle Genetics (institution). He is a member of the Speakers' Bureau for AstraZeneca/Medimmune, Genentech, and Merck. He has equity and is a Scientific Advisory Board Member for EpiVax Oncology. He is also on the Steering/Scientific Advisory Committee for Merck and Nektar.
Robert Dreicer, MD, MS, MACP, FASCO–has disclosed that he is a consultant for Astellas, Eisai, Janssen, Orion, Novartis, Pfizer, Seattle Genetics, and Vizuri. He also receives grant/research support from Exelixis, Merck, Roche, and Seattle Genetics.
Ashish M. Kamat, MD, MBBS, FACS–has disclosed that he is a consultant for Arquer, Asieris, Astra Zeneca, BioClin Therapeutics, BMS Cepheid, Cold Genesys, Eisai, Ferring; FKD IBCG Imagin MDxHealth Medac, Merck, Pfizer, Photocure Roviant, Sessen Bio Theralase TMC Innovation, US Biotest. 
Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.

Peer Reviewer
Bishoy Morris Faltas, MD–has no relevant financial relationships to disclose in relation to the content of this activity.


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

 

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or register to take this course.